Article(id=1208144411159020139, tenantId=1146029695717560320, journalId=1189873630562394117, issueId=1208144409313526368, articleNumber=null, orderNo=null, doi=10.11855/j.issn.0577-7402.2022.03.0292, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=research-article, receivedDate=1628611200000, receivedDateStr=2021-08-11, revisedDate=null, revisedDateStr=null, acceptedDate=1633968000000, acceptedDateStr=2021-10-12, onlineDate=1765973673858, onlineDateStr=2025-12-17, pubDate=1648396800000, pubDateStr=2022-03-28, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1765973673858, onlineIssueDateStr=2025-12-17, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1765973673858, creator=13701087609, updateTime=1765973673858, updator=13701087609, issue=Issue{id=1208144409313526368, tenantId=1146029695717560320, journalId=1189873630562394117, year='2022', volume='47', issue='3', pageStart='213', pageEnd='319', issueExtLink='null', onlineDate='null', pubDate='null', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=0, createTime=1765973673415, creator=13701087609, updateTime=1765974822867, updator=13701087609, preIssue=null, nextIssue=null, ext={EN=IssueExt(id=1208149230531756320, tenantId=1146029695717560320, journalId=1189873630562394117, issueId=1208144409313526368, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1208149230531756321, tenantId=1146029695717560320, journalId=1189873630562394117, issueId=1208144409313526368, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null}, startPage=292, endPage=298, ext={EN=ArticleExt(id=1208144411544896118, articleId=1208144411159020139, tenantId=1146029695717560320, journalId=1189873630562394117, language=EN, title=Progress of clinical research and application of PCSK9 inhibitors on the management of dyslipidaemias, columnId=1190243275882729994, journalTitle=Medical Journal of Chinese People’s Liberation Army, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

To strengthen the management of dyslipidaemias in patients with atherosclerotic cardiovascular disease (ASCVD)is regarded as an important measure to delay the disease progression and improve the long-term prognosis. However, there are still a high proportion of domestic patients, whose lipids levels are not up to the standard after receiving conventional lipid lowering therapy, causing an unoptimistic form of lipids management of ASCVD patients in China. As researchers found the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, targeted PCSK9 inhibitors have been put into clinical researches gradually and accumulated series evidence on efficacy and safety. Main literature referred to the clinical research and application progress of PCSK9 inhibitors were reviewed in present paper, to provide a reference for future clinical practice.

, correspAuthors=Yun-Dai Chen, authorNote=null, correspAuthorsNote=, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, authorCompany=null, fund=null, authors=null, authorsList=Xi Wang, Jun-Jie Yang, Yun-Dai Chen), CN=ArticleExt(id=1208144412014658176, articleId=1208144411159020139, tenantId=1146029695717560320, journalId=1189873630562394117, language=CN, title=PCSK9抑制剂在血脂管理中的临床研究与应用进展, columnId=1190243276029530637, journalTitle=解放军医学杂志, columnName=综述, runingTitle=null, highlight=null, articleAbstract=

加强动脉粥样硬化性心血管疾病(ASCVD)患者的血脂管理，是延缓其疾病进展并改善远期预后的重要举措。然而，目前我国ASCVD患者血脂管理形势不容乐观，仍有较高比例的患者在接受传统降脂药物治疗后血脂管理并不达标。已有研究发现，前蛋白转化酶枯草杆菌蛋白酶/kexin9型(PCSK9)在血脂代谢中具有重要作用，而针对此靶点研发的PCSK9抑制剂投入临床后已积累了大量有效性与安全性方面的数据。本文主要针对PCSK9抑制剂的临床研究进行综述，为其在临床实践中的进一步应用提供参考依据。

, correspAuthors=陈韵岱, authorNote=null, correspAuthorsNote=, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=8ig7dj3afwPnf8YpDw25GA==, magXml=IVd8X9+yCYExoxP4hCUXhA==, pdfUrl=null, pdf=F2Cd1W/bmOybfxDmqb9CJg==, pdfFileSize=1053643, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=B2gWPL3dvV0pPgnIWsITZQ==, mapNumber=null, authorCompany=null, fund=null, authors=, authorsList=王玺, 杨俊杰, 陈韵岱)}, authors=[Author(id=1208144412480225947, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1208144412627026595, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, authorId=1208144412480225947, language=EN, stringName=Xi Wang, firstName=Xi, middleName=null, lastName=Wang, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=^{1, 2}, address=¹Medical School of Chinese PLA, Beijing 100853, China
²Department of Cardiovascular Medicine, Chinese PLA General Hospital, Beijing 100048, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1208144412731884205, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, authorId=1208144412480225947, language=CN, stringName=王玺, firstName=玺, middleName=null, lastName=王, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=^{1, 2}, address=¹解放军医学院，北京 100853
²解放军总医院心血管病医学部，北京 100048, bio={"content":"

王玺，博士研究生，主要从事冠心病无创影像与临床方面的研究

"}, bioImg=null, bioContent=

王玺，博士研究生，主要从事冠心病无创影像与临床方面的研究

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1208144412329230993, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, xref=1, ext=[AuthorCompanyExt(id=1208144412333425298, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, companyId=1208144412329230993, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹Medical School of Chinese PLA, Beijing 100853, China), AuthorCompanyExt(id=1208144412341813907, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, companyId=1208144412329230993, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹解放军医学院，北京 100853)]), AuthorCompany(id=1208144412408922775, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, xref=2, ext=[AuthorCompanyExt(id=1208144412413117080, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, companyId=1208144412408922775, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=²Department of Cardiovascular Medicine, Chinese PLA General Hospital, Beijing 100048, China), AuthorCompanyExt(id=1208144412421505689, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, companyId=1208144412408922775, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=²解放军总医院心血管病医学部，北京 100048)])]), Author(id=1208144412857713333, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1208144412949988028, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, authorId=1208144412857713333, language=EN, stringName=Jun-Jie Yang, firstName=Jun-Jie, middleName=null, lastName=Yang, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=², address=²Department of Cardiovascular Medicine, Chinese PLA General Hospital, Beijing 100048, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1208144413050651333, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, authorId=1208144412857713333, language=CN, stringName=杨俊杰, firstName=俊杰, middleName=null, lastName=杨, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=², address=²解放军总医院心血管病医学部，北京 100048, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1208144412408922775, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, xref=2, ext=[AuthorCompanyExt(id=1208144412413117080, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, companyId=1208144412408922775, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=²Department of Cardiovascular Medicine, Chinese PLA General Hospital, Beijing 100048, China), AuthorCompanyExt(id=1208144412421505689, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, companyId=1208144412408922775, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=²解放军总医院心血管病医学部，北京 100048)])]), Author(id=1208144413151314635, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=cyundai@vip.163.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1208144413264560848, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, authorId=1208144413151314635, language=EN, stringName=Yun-Dai Chen, firstName=Yun-Dai, middleName=null, lastName=Chen, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=^{2, *}, address=²Department of Cardiovascular Medicine, Chinese PLA General Hospital, Beijing 100048, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1208144413449110231, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, authorId=1208144413151314635, language=CN, stringName=陈韵岱, firstName=韵岱, middleName=null, lastName=陈, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=^{2, *}, address=²解放军总医院心血管病医学部，北京 100048, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1208144412408922775, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, xref=2, ext=[AuthorCompanyExt(id=1208144412413117080, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, companyId=1208144412408922775, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=²Department of Cardiovascular Medicine, Chinese PLA General Hospital, Beijing 100048, China), AuthorCompanyExt(id=1208144412421505689, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, companyId=1208144412408922775, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=²解放军总医院心血管病医学部，北京 100048)])])], keywords=[Keyword(id=1208144413558162139, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, language=EN, orderNo=1, keyword=coronary artery disease), Keyword(id=1208144413654631138, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, language=EN, orderNo=2, keyword=dyslipidaemias), Keyword(id=1208144413822403303, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, language=EN, orderNo=3, keyword=proprotein convertase subtilisin/kexin type 9 inhibitors), Keyword(id=1208144413994369774, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, language=CN, orderNo=1, keyword=冠心病), Keyword(id=1208144414116004593, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, language=CN, orderNo=2, keyword=血脂异常), Keyword(id=1208144414199890677, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, language=CN, orderNo=3, keyword=PCSK9抑制剂)], refs=[Reference(id=1208144414787093277, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2020, volume=35, issue=9, pageStart=833, pageEnd=854, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=The Writing Committee of the Report on Cardiovascular Health and Diseases in China, journalName=Chin Circ J, refType=null, unstructuredReference=The Writing Committee of the Report on Cardiovascular Health and Diseases in China. Report on cardiovascular health and diseases in China 2019: an updated summary[J]. Chin Circ J, 2020, 35(9): 833-854., articleTitle=Report on cardiovascular health and diseases in China 2019: an updated summary, refAbstract=null), Reference(id=1208144414896145189, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2020, volume=null, issue=9, pageStart=833, pageEnd=854, url=null, language=null, rfNumber=[1], rfOrder=1, authorNames=中国心血管健康与疾病报告编写组, journalName=中国循环杂志, refType=null, unstructuredReference=[中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2019概要[J]. 中国循环杂志, 2020, 35(9): 833-854.], articleTitle=中国心血管健康与疾病报告2019概要, refAbstract=null), Reference(id=1208144415038751537, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2003, volume=34, issue=2, pageStart=154, pageEnd=156, url=null, language=null, rfNumber=[2], rfOrder=2, authorNames=Abifadel M, Varret M, Rabès JP, journalName=Nat Genet, refType=null, unstructuredReference=Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia[J]. Nat Genet, 2003, 34(2): 154-156., articleTitle=Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, refAbstract=null), Reference(id=1208144415177163578, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2006, volume=15, issue=9, pageStart=1551, pageEnd=1558, url=null, language=null, rfNumber=[3], rfOrder=3, authorNames=Cameron J, Holla ØL, Ranheim T, journalName=Hum Mol Genet, refType=null, unstructuredReference=Cameron J, Holla ØL, Ranheim T, et al. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors[J]. Hum Mol Genet, 2006, 15(9): 1551-1558., articleTitle=Effect of mutations in the PCSK9 gene on the cell surface LDL receptors, refAbstract=null), Reference(id=1208144415395267397, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2006, volume=354, issue=12, pageStart=1264, pageEnd=1272, url=null, language=null, rfNumber=[4], rfOrder=4, authorNames=Cohen JC, Boerwinkle E, Mosley TH Jr, journalName=N Engl J Med, refType=null, unstructuredReference=Cohen JC, Boerwinkle E, Mosley TH Jr, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease[J]. N Engl J Med, 2006, 354(12): 1264-1272., articleTitle=Sequence variations in PCSK9, low LDL, and protection against coronary heart disease, refAbstract=null), Reference(id=1208144415479153487, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2007, volume=15, issue=5, pageStart=545, pageEnd=552, url=null, language=null, rfNumber=[5], rfOrder=5, authorNames=Piper DE, Jackson S, Liu Q, journalName=Structure, refType=null, unstructuredReference=Piper DE, Jackson S, Liu Q, et al. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol[J]. Structure, 2007, 15(5): 545-552., articleTitle=The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol, refAbstract=null), Reference(id=1208144415558845268, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2009, volume=106, issue=24, pageStart=9820, pageEnd=9825, url=null, language=null, rfNumber=[6], rfOrder=6, authorNames=Chan JC, Piper DE, Cao Q, journalName=Proc Natl Acad Sci U S A, refType=null, unstructuredReference=Chan JC, Piper DE, Cao Q, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates[J]. Proc Natl Acad Sci U S A, 2009, 106(24): 9820-9825., articleTitle=A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates, refAbstract=null), Reference(id=1208144415663702876, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2012, volume=60, issue=19, pageStart=1888, pageEnd=1898, url=null, language=null, rfNumber=[7], rfOrder=7, authorNames=Dias CS, Shaywitz AJ, Wasserman SM, journalName=J Am Coll Cardiol, refType=null, unstructuredReference=Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins[J]. J Am Coll Cardiol, 2012, 60(19): 1888-1898., articleTitle=Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins, refAbstract=null), Reference(id=1208144415751783270, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2017, volume=57, issue=5, pageStart=616, pageEnd=626, url=null, language=null, rfNumber=[8], rfOrder=8, authorNames=Gibbs JP, Doshi S, Kuchimanchi M, journalName=J Clin Pharmacol, refType=null, unstructuredReference=Gibbs JP, Doshi S, Kuchimanchi M, et al. Impact of target-mediated elimination on the dose and regimen of evolocumab, a human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9)[J]. J Clin Pharmacol, 2017, 57(5): 616-626., articleTitle=Impact of target-mediated elimination on the dose and regimen of evolocumab, a human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), refAbstract=null), Reference(id=1208144415860835182, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2012, volume=380, issue=9858, pageStart=1995, pageEnd=2006, url=null, language=null, rfNumber=[9], rfOrder=9, authorNames=Koren MJ, Scott R, Kim JB, journalName=Lancet, refType=null, unstructuredReference=Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study[J]. Lancet, 2012, 380(9858):1995-2006., articleTitle=Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study, refAbstract=null), Reference(id=1208144416049578867, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2014, volume=63, issue=5, pageStart=430, pageEnd=433, url=null, language=null, rfNumber=[10], rfOrder=10, authorNames=Desai NR, Giugliano RP, Zhou J, journalName=J Am Coll Cardiol, refType=null, unstructuredReference=Desai NR, Giugliano RP, Zhou J, et al. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57)[J]. J Am Coll Cardiol, 2014, 63(5): 430-433., articleTitle=AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57), refAbstract=null), Reference(id=1208144416171213689, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2012, volume=380, issue=9858, pageStart=2007, pageEnd=2017, url=null, language=null, rfNumber=[11], rfOrder=11, authorNames=Giugliano RP, Desai NR, Kohli P, journalName=Lancet, refType=null, unstructuredReference=Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study[J]. Lancet, 2012, 380(9858): 2007-2017., articleTitle=Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study, refAbstract=null), Reference(id=1208144416330597250, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2012, volume=308, issue=23, pageStart=2497, pageEnd=2506, url=null, language=null, rfNumber=[12], rfOrder=12, authorNames=Sullivan D, Olsson AG, Scott R, journalName=JAMA, refType=null, unstructuredReference=Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial[J]. JAMA, 2012, 308(23): 2497-2506., articleTitle=Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial, refAbstract=null), Reference(id=1208144416439649158, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2014, volume=78, issue=5, pageStart=1073, pageEnd=1082, url=null, language=null, rfNumber=[13], rfOrder=13, authorNames=Hirayama A, Honarpour N, Yoshida M, journalName=Circ J, refType=null, unstructuredReference=Hirayama A, Honarpour N, Yoshida M, et al. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study[J]. Circ J, 2014, 78(5): 1073-1082., articleTitle=Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study, refAbstract=null), Reference(id=1208144416536118159, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2015, volume=385, issue=9965, pageStart=341, pageEnd=350, url=null, language=null, rfNumber=[14], rfOrder=14, authorNames=Raal FJ, Honarpour N, Blom DJ, journalName=Lancet, refType=null, unstructuredReference=Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia(TESLA Part B): a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2015, 385(9965): 341-350., articleTitle=Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia(TESLA Part B): a randomised, double-blind, placebo-controlled trial, refAbstract=null), Reference(id=1208144416620004248, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2014, volume=129, issue=2, pageStart=234, pageEnd=243, url=null, language=null, rfNumber=[15], rfOrder=15, authorNames=Koren MJ, Giugliano RP, Raal FJ, journalName=Circulation, refType=null, unstructuredReference=Koren MJ, Giugliano RP, Raal FJ, et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C(OSLER) randomized trial[J]. Circulation, 2014, 129(2): 234-243., articleTitle=Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C(OSLER) randomized trial, refAbstract=null), Reference(id=1208144416737444770, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2019, volume=74, issue=17, pageStart=2132, pageEnd=2146, url=null, language=null, rfNumber=[16], rfOrder=16, authorNames=Koren MJ, Sabatine MS, Giugliano RP, journalName=J Am Coll Cardiol, refType=null, unstructuredReference=Koren MJ, Sabatine MS, Giugliano RP, et al. Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia[J]. J Am Coll Cardiol, 2019, 74(17):2132-2146., articleTitle=Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia, refAbstract=null), Reference(id=1208144416854885288, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2017, volume=81, issue=7, pageStart=1029, pageEnd=1035, url=null, language=null, rfNumber=[17], rfOrder=17, authorNames=Hirayama A, Yamashita S, Inomata H, journalName=Circ J, refType=null, unstructuredReference=Hirayama A, Yamashita S, Inomata H, et al. One-year efficacy and safety of evolocumab in Japanese patients - A pooled analysis from the open-label extension OSLER studies[J]. Circ J, 2017, 81(7): 1029-1035., articleTitle=One-year efficacy and safety of evolocumab in Japanese patients - A pooled analysis from the open-label extension OSLER studies, refAbstract=null), Reference(id=1208144416942965679, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2019, volume=83, issue=5, pageStart=971, pageEnd=977, url=null, language=null, rfNumber=[18], rfOrder=18, authorNames=Hirayama A, Yamashita S, Ruzza A, journalName=Circ J, refType=null, unstructuredReference=Hirayama A, Yamashita S, Ruzza A, et al. Long-term treatment with evolocumab among Japanese patients - final report of the OSLER open-label extension studies[J]. Circ J, 2019, 83(5):971-977., articleTitle=Long-term treatment with evolocumab among Japanese patients - final report of the OSLER open-label extension studies, refAbstract=null), Reference(id=1208144417031046068, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2014, volume=63, issue=23, pageStart=2531, pageEnd=2540, url=null, language=null, rfNumber=[19], rfOrder=19, authorNames=Koren MJ, Lundqvist P, Bolognese M, journalName=J Am Coll Cardiol, refType=null, unstructuredReference=Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab[J]. J Am Coll Cardiol, 2014, 63(23): 2531-2540., articleTitle=Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab, refAbstract=null), Reference(id=1208144417127515068, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2014, volume=311, issue=18, pageStart=1870, pageEnd=1882, url=null, language=null, rfNumber=[20], rfOrder=20, authorNames=Robinson JG, Nedergaard BS, Rogers WJ, journalName=JAMA, refType=null, unstructuredReference=Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial[J]. JAMA, 2014, 311(18): 1870-1882., articleTitle=Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial, refAbstract=null), Reference(id=1208144417240761284, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2017, volume=390, issue=10106, pageStart=1962, pageEnd=1971, url=null, language=null, rfNumber=[21], rfOrder=21, authorNames=Giugliano RP, Pedersen TR, Park JG, journalName=Lancet, refType=null, unstructuredReference=Giugliano RP, Pedersen TR, Park JG, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial[J]. Lancet, 2017, 390(10106):1962-1971., articleTitle=Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial, refAbstract=null), Reference(id=1208144417312064455, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2014, volume=63, issue=23, pageStart=2541, pageEnd=2548, url=null, language=null, rfNumber=[22], rfOrder=22, authorNames=Stroes E, Colquhoun D, Sullivan D, journalName=J Am Coll Cardiol, refType=null, unstructuredReference=Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab[J]. J Am Coll Cardiol, 2014, 63(23): 2541-2548., articleTitle=Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab, refAbstract=null), Reference(id=1208144417395950541, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2016, volume=315, issue=15, pageStart=1580, pageEnd=1590, url=null, language=null, rfNumber=[23], rfOrder=23, authorNames=Nissen SE, Stroes E, Dent-Acosta RE, journalName=JAMA, refType=null, unstructuredReference=Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial[J]. JAMA, 2016, 315(15): 1580-1590., articleTitle=Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial, refAbstract=null), Reference(id=1208144417559528406, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2018, volume=32, issue=4, pageStart=365, pageEnd=372, url=null, language=null, rfNumber=[24], rfOrder=24, authorNames=Cho L, Dent R, Stroes ESG, journalName=Cardiovasc Drugs Ther, refType=null, unstructuredReference=Cho L, Dent R, Stroes ESG, et al. Persistent safety and efficacy of evolocumab in patients with statin intolerance: a subset analysis of the OSLER open-label extension studies[J]. Cardiovasc Drugs Ther, 2018, 32(4): 365-372., articleTitle=Persistent safety and efficacy of evolocumab in patients with statin intolerance: a subset analysis of the OSLER open-label extension studies, refAbstract=null), Reference(id=1208144417647608796, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2014, volume=57, issue=12, pageStart=2444, pageEnd=2452, url=null, language=null, rfNumber=[25], rfOrder=25, authorNames=Erqou S, Lee CC, Adler AI, journalName=Diabetologia, refType=null, unstructuredReference=Erqou S, Lee CC, Adler AI. Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis[J]. Diabetologia, 2014, 57(12): 2444-2452., articleTitle=Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis, refAbstract=null), Reference(id=1208144417723106275, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2017, volume=19, issue=1, pageStart=98, pageEnd=107, url=null, language=null, rfNumber=[26], rfOrder=26, authorNames=Blom DJ, Koren MJ, Roth E, journalName=Diabetes Obes Metab, refType=null, unstructuredReference=Blom DJ, Koren MJ, Roth E, et al. Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome[J]. Diabetes Obes Metab, 2017, 19(1): 98-107., articleTitle=Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome, refAbstract=null), Reference(id=1208144417794409452, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2017, volume=120, issue=9, pageStart=1521, pageEnd=1527, url=null, language=null, rfNumber=[27], rfOrder=27, authorNames=Sattar N, Toth PP, Blom DJ, journalName=Am J Cardiol, refType=null, unstructuredReference=Sattar N, Toth PP, Blom DJ, et al. Effect of the proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab on glycemia, body weight, and new-onset diabetes mellitus[J]. Am J Cardiol, 2017, 120(9): 1521-1527., articleTitle=Effect of the proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab on glycemia, body weight, and new-onset diabetes mellitus, refAbstract=null), Reference(id=1208144417895072752, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2019, volume=62, issue=6, pageStart=948, pageEnd=958, url=null, language=null, rfNumber=[28], rfOrder=28, authorNames=Rosenson RS, Daviglus ML, Handelsman Y, journalName=Diabetologia, refType=null, unstructuredReference=Rosenson RS, Daviglus ML, Handelsman Y, et al. Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study[J]. Diabetologia, 2019, 62(6): 948-958., articleTitle=Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study, refAbstract=null), Reference(id=1208144418104787959, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2019, volume=21, issue=6, pageStart=1455, pageEnd=1463, url=null, language=null, rfNumber=[29], rfOrder=29, authorNames=Lorenzatti AJ, Eliaschewitz FG, Chen Y, journalName=Diabetes Obes Metab, refType=null, unstructuredReference=Lorenzatti AJ, Eliaschewitz FG, Chen Y, et al. Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial[J]. Diabetes Obes Metab, 2019, 21(6): 1455-1463., articleTitle=Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial, refAbstract=null), Reference(id=1208144418209645566, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2019, volume=21, issue=6, pageStart=1464, pageEnd=1473, url=null, language=null, rfNumber=[30], rfOrder=30, authorNames=Chen Y, Yuan Z, Lu J, journalName=Diabetes Obes Metab, refType=null, unstructuredReference=Chen Y, Yuan Z, Lu J, et al. Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre-specified analysis of the Chinese population from the BERSON clinical trial[J]. Diabetes Obes Metab, 2019, 21(6):1464-1473., articleTitle=Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre-specified analysis of the Chinese population from the BERSON clinical trial, refAbstract=null), Reference(id=1208144418293530627, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2017, volume=5, issue=12, pageStart=941, pageEnd=950, url=null, language=null, rfNumber=[31], rfOrder=31, authorNames=Sabatine MS, Leiter LA, Wiviott SD, journalName=Lancet Diabetes Endocrinol, refType=null, unstructuredReference=Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial[J]. Lancet Diabetes Endocrinol, 2017, 5(12): 941-950., articleTitle=Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial, refAbstract=null), Reference(id=1208144418398388234, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2017, volume=40, issue=2, pageStart=59, pageEnd=65, url=null, language=null, rfNumber=[32], rfOrder=32, authorNames=Giugliano RP, Mach F, Zavitz K, journalName=Clin Cardiol, refType=null, unstructuredReference=Giugliano RP, Mach F, Zavitz K, et al. Design and rationale of the EBBINGHAUS trial: a phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial[J]. Clin Cardiol, 2017, 40(2): 59-65., articleTitle=Design and rationale of the EBBINGHAUS trial: a phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial, refAbstract=null), Reference(id=1208144418507440141, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2017, volume=377, issue=7, pageStart=633, pageEnd=643, url=null, language=null, rfNumber=[33], rfOrder=33, authorNames=Giugliano RP, Mach F, Zavitz K, journalName=N Engl J Med, refType=null, unstructuredReference=Giugliano RP, Mach F, Zavitz K, et al. Cognitive function in a randomized trial of evolocumab[J]. N Engl J Med, 2017, 377(7):633-643., articleTitle=Cognitive function in a randomized trial of evolocumab, refAbstract=null), Reference(id=1208144418608103440, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2020, volume=75, issue=18, pageStart=2283, pageEnd=2293, url=null, language=null, rfNumber=[34], rfOrder=34, authorNames=Gencer B, Mach F, Guo J, journalName=J Am Coll Cardiol, refType=null, unstructuredReference=Gencer B, Mach F, Guo J, et al. Cognition after lowering LDL-cholesterol with evolocumab[J]. J Am Coll Cardiol, 2020, 75(18): 2283-2293., articleTitle=Cognition after lowering LDL-cholesterol with evolocumab, refAbstract=null), Reference(id=1208144418792652825, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2020, volume=11, issue=null, pageStart=595819, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=35, authorNames=Katzmann JL, Gouni-Berthold I, Laufs U, journalName=Front Physiol, refType=null, unstructuredReference=Katzmann JL, Gouni-Berthold I, Laufs U. PCSK9 inhibition: insights from clinical trials and future prospects[J]. Front Physiol, 2020, 11: 595819., articleTitle=PCSK9 inhibition: insights from clinical trials and future prospects, refAbstract=null), Reference(id=1208144418922676257, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2012, volume=126, issue=20, pageStart=2408, pageEnd=2417, url=null, language=null, rfNumber=[36], rfOrder=36, authorNames=Raal F, Scott R, Somaratne R, journalName=Circulation, refType=null, unstructuredReference=Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD)randomized trial[J]. Circulation, 2012, 126(20): 2408-2417., articleTitle=Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD)randomized trial, refAbstract=null), Reference(id=1208144419002368039, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2015, volume=385, issue=9965, pageStart=331, pageEnd=340, url=null, language=null, rfNumber=[37], rfOrder=37, authorNames=Raal FJ, Stein EA, Dufour R, journalName=Lancet, refType=null, unstructuredReference=Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2015, 385(9965): 331-340., articleTitle=PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial, refAbstract=null), Reference(id=1208144419103031337, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2017, volume=11, issue=6, pageStart=1448, pageEnd=1457, url=null, language=null, rfNumber=[38], rfOrder=38, authorNames=Hovingh GK, Raal FJ, Dent R, journalName=J Clin Lipidol, refType=null, unstructuredReference=Hovingh GK, Raal FJ, Dent R, et al. Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia[J]. J Clin Lipidol, 2017, 11(6): 1448-1457., articleTitle=Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia, refAbstract=null), Reference(id=1208144419191111727, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2018, volume=12, issue=5, pageStart=1199, pageEnd=1207, url=null, language=null, rfNumber=[39], rfOrder=39, authorNames=Gaudet D, Langslet G, Gidding SS, journalName=J Clin Lipidol, refType=null, unstructuredReference=Gaudet D, Langslet G, Gidding SS, et al. Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: rationale and design of the HAUSER-RCT study[J]. J Clin Lipidol, 2018, 12(5):1199-1207., articleTitle=Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: rationale and design of the HAUSER-RCT study, refAbstract=null), Reference(id=1208144419295969332, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2013, volume=128, issue=19, pageStart=2113, pageEnd=2120, url=null, language=null, rfNumber=[40], rfOrder=40, authorNames=Stein EA, Honarpour N, Wasserman SM, journalName=Circulation, refType=null, unstructuredReference=Stein EA, Honarpour N, Wasserman SM, et al. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia[J]. Circulation, 2013, 128(19): 2113-2120., articleTitle=Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia, refAbstract=null), Reference(id=1208144419413409852, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2017, volume=5, issue=4, pageStart=280, pageEnd=290, url=null, language=null, rfNumber=[41], rfOrder=41, authorNames=Raal FJ, Hovingh GK, Blom D, journalName=Lancet Diabetes Endocrinol, refType=null, unstructuredReference=Raal FJ, Hovingh GK, Blom D, et al. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study[J]. Lancet Diabetes Endocrinol, 2017, 5(4): 280-290., articleTitle=Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study, refAbstract=null), Reference(id=1208144419497295935, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2020, volume=41, issue=1, pageStart=111, pageEnd=188, url=null, language=null, rfNumber=[42], rfOrder=42, authorNames=Mach F, Baigent C, Catapano AL, journalName=Eur Heart J, refType=null, unstructuredReference=Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk[J]. Eur Heart J, 2020, 41(1): 111-188., articleTitle=2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk, refAbstract=null), Reference(id=1208144419576987719, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2020, volume=9, issue=5, pageStart=e014129, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=43, authorNames=Toth PP, Jones SR, Monsalvo ML, journalName=J Am Heart Assoc, refType=null, unstructuredReference=Toth PP, Jones SR, Monsalvo ML, et al. Effect of evolocumab on non-high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a): a pooled analysis of phase 2 and phase 3 studies[J]. J Am Heart Assoc, 2020, 9(5): e014129., articleTitle=Effect of evolocumab on non-high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a): a pooled analysis of phase 2 and phase 3 studies, refAbstract=null), Reference(id=1208144419665068107, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2019, volume=139, issue=12, pageStart=1483, pageEnd=1492, url=null, language=null, rfNumber=[44], rfOrder=44, authorNames=O'Donoghue ML, Fazio S, Giugliano RP, journalName=Circulation, refType=null, unstructuredReference=O'Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk[J]. Circulation, 2019, 139(12): 1483-1492., articleTitle=Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk, refAbstract=null), Reference(id=1208144419769925713, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2010, volume=376, issue=9753, pageStart=1670, pageEnd=1681, url=null, language=null, rfNumber=[45], rfOrder=45, authorNames=Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, journalName=Lancet, refType=null, unstructuredReference=Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials[J]. Lancet, 2010, 376(9753): 1670-1681., articleTitle=Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials, refAbstract=null), Reference(id=1208144419858006101, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2016, volume=173, issue=null, pageStart=94, pageEnd=101, url=null, language=null, rfNumber=[46], rfOrder=46, authorNames=Sabatine MS, Giugliano RP, Keech A, journalName=Am Heart J, refType=null, unstructuredReference=Sabatine MS, Giugliano RP, Keech A, et al. Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial[J]. Am Heart J, 2016, 173: 94-101., articleTitle=Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial, refAbstract=null), Reference(id=1208144419983835226, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2017, volume=376, issue=18, pageStart=1713, pageEnd=1722, url=null, language=null, rfNumber=[47], rfOrder=47, authorNames=Sabatine MS, Giugliano RP, Keech AC, journalName=N Engl J Med, refType=null, unstructuredReference=Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med, 2017, 376(18): 1713-1722., articleTitle=Evolocumab and clinical outcomes in patients with cardiovascular disease, refAbstract=null), Reference(id=1208144420071915614, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2020, volume=5, issue=8, pageStart=952, pageEnd=957, url=null, language=null, rfNumber=[48], rfOrder=48, authorNames=Gencer B, Mach F, Murphy SA, journalName=JAMA Cardiol, refType=null, unstructuredReference=Gencer B, Mach F, Murphy SA, et al. Efficacy of evolocumab on cardiovascular outcomes in patients with recent myocardial infarction: a prespecified secondary analysis from the FOURIER trial[J]. JAMA Cardiol, 2020, 5(8): 952-957., articleTitle=Efficacy of evolocumab on cardiovascular outcomes in patients with recent myocardial infarction: a prespecified secondary analysis from the FOURIER trial, refAbstract=null), Reference(id=1208144420172578917, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2020, volume=5, issue=7, pageStart=787, pageEnd=793, url=null, language=null, rfNumber=[49], rfOrder=49, authorNames=Wiviott SD, Giugliano RP, Morrow DA, journalName=JAMA Cardiol, refType=null, unstructuredReference=Wiviott SD, Giugliano RP, Morrow DA, et al. Effect of evolocumab on type and size of subsequent myocardial infarction: a prespecified analysis of the FOURIER randomized clinical trial[J]. JAMA Cardiol, 2020, 5(7): 787-793., articleTitle=Effect of evolocumab on type and size of subsequent myocardial infarction: a prespecified analysis of the FOURIER randomized clinical trial, refAbstract=null), Reference(id=1208144420310990955, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2020, volume=95, issue=5, pageStart=998, pageEnd=1014, url=null, language=null, rfNumber=[50], rfOrder=50, authorNames=Singh M, McEvoy JW, Khan SU, journalName=Mayo Clin Proc, refType=null, unstructuredReference=Singh M, McEvoy JW, Khan SU, et al. Comparison of transatlantic approaches to lipid management: the AHA/ACC/multisociety guidelines vs the ESC/EAS guidelines[J]. Mayo Clin Proc, 2020, 95(5): 998-1014., articleTitle=Comparison of transatlantic approaches to lipid management: the AHA/ACC/multisociety guidelines vs the ESC/EAS guidelines, refAbstract=null), Reference(id=1208144420432625775, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2016, volume=44, issue=8, pageStart=665, pageEnd=670, url=null, language=null, rfNumber=[51], rfOrder=51, authorNames=Li Y, Zhao SP, Ye P, journalName=Chin J Cardiol, refType=null, unstructuredReference=Li Y, Zhao SP, Ye P, et al. Status of cholesterol goal attainment for the primary and secondary prevention of atherosclerotic cardiovascular disease in dyslipidemia patients receiving lipid-lowering therapy: DYSIS-China subgroup analysis[J]. Chin J Cardiol, 2016, 44(8): 665-670., articleTitle=Status of cholesterol goal attainment for the primary and secondary prevention of atherosclerotic cardiovascular disease in dyslipidemia patients receiving lipid-lowering therapy: DYSIS-China subgroup analysis, refAbstract=null), Reference(id=1208144420529094772, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2016, volume=44, issue=8, pageStart=665, pageEnd=670, url=null, language=null, rfNumber=[51], rfOrder=52, authorNames=李勇, 赵水平, 叶平, journalName=中华心血管病杂志, refType=null, unstructuredReference=[李勇, 赵水平, 叶平, 等. 中国血脂异常门诊患者调脂治疗一级和二级预防达标现状：DYSIS-China亚组分析[J]. 中华心血管病杂志, 2016, 44(8):665-670.], articleTitle=中国血脂异常门诊患者调脂治疗一级和二级预防达标现状：DYSIS-China亚组分析, refAbstract=null), Reference(id=1208144420604592248, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2018, volume=14, issue=null, pageStart=2255, pageEnd=2264, url=null, language=null, rfNumber=[52], rfOrder=53, authorNames=Jiang J, Zhou YJ, Li JJ, journalName=Ther Clin Risk Manag, refType=null, unstructuredReference=Jiang J, Zhou YJ, Li JJ, et al. Uncontrolled hyperlipidemia in Chinese patients who experienced acute coronary syndrome: an observational study[J]. Ther Clin Risk Manag, 2018, 14: 2255-2264., articleTitle=Uncontrolled hyperlipidemia in Chinese patients who experienced acute coronary syndrome: an observational study, refAbstract=null), Reference(id=1208144420701061243, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2020, volume=59, issue=1, pageStart=18, pageEnd=22, url=null, language=null, rfNumber=[53], rfOrder=54, authorNames=China Cholesterol Education Program (CCEP) Working Committee, Atherosclerosis Thrombosis Prevention and Control Subcommittee of Chinese International Exchange and Promotion Association for Medical and Healthcare, Cardiovascular Disease Subcommittee of China Association of Gerontology and Geriatrics, journalName=Chin J Intern Med, refType=null, unstructuredReference=China Cholesterol Education Program (CCEP) Working Committee, Atherosclerosis Thrombosis Prevention and Control Subcommittee of Chinese International Exchange and Promotion Association for Medical and Healthcare, Cardiovascular Disease Subcommittee of China Association of Gerontology and Geriatrics, et al. China cholesterol education program (CCEP)expert advice for the management of dyslipidaemias to reduce cardiovascular risk (2019)[J]. Chin J Intern Med, 2020, 59(1):18-22., articleTitle=China cholesterol education program (CCEP)expert advice for the management of dyslipidaemias to reduce cardiovascular risk (2019), refAbstract=null), Reference(id=1208144420780753023, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2020, volume=null, issue=1, pageStart=18, pageEnd=22, url=null, language=null, rfNumber=[53], rfOrder=55, authorNames=中国胆固醇教育计划工作委员会, 中国医疗保健国际交流促进会动脉粥样硬化血栓疾病防治分会, 中国老年学和老年医学学会心血管病分会, journalName=中华内科杂志, refType=null, unstructuredReference=[中国胆固醇教育计划工作委员会, 中国医疗保健国际交流促进会动脉粥样硬化血栓疾病防治分会, 中国老年学和老年医学学会心血管病分会, 等. 中国胆固醇教育计划调脂治疗降低心血管事件专家建议(2019)[J]. 中华内科杂志, 2020, 59(1): 18-22.], articleTitle=中国胆固醇教育计划调脂治疗降低心血管事件专家建议(2019), refAbstract=null), Reference(id=1208144420856250499, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2020, volume=48, issue=4, pageStart=280, pageEnd=286, url=null, language=null, rfNumber=[54], rfOrder=56, authorNames=Atherosclerosis and Coronary Heart Disease Working Group of Chinese Society of Cardiology, Editorial Board of Chinese Journal of Cardiology, journalName=Chin J Cardiol, refType=null, unstructuredReference=Atherosclerosis and Coronary Heart Disease Working Group of Chinese Society of Cardiology, Editorial Board of Chinese Journal of Cardiology. Chinese expert consensus on lipid management of very high-risk atherosclerotic cardiovascular disease patients[J]. Chin J Cardiol, 2020, 48(4): 280-286., articleTitle=Chinese expert consensus on lipid management of very high-risk atherosclerotic cardiovascular disease patients, refAbstract=null), Reference(id=1208144420956913797, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, doi=null, pmid=null, pmcid=null, year=2020, volume=null, issue=4, pageStart=280, pageEnd=286, url=null, language=null, rfNumber=[54], rfOrder=57, authorNames=中华医学会心血管病学分会动脉粥样硬化与冠心病学组, 中华心血管病杂志编辑委员会, journalName=中华心血管病杂志, refType=null, unstructuredReference=[中华医学会心血管病学分会动脉粥样硬化与冠心病学组, 中华心血管病杂志编辑委员会. 超高危动脉粥样硬化性心血管疾病患者血脂管理中国专家共识[J]. 中华心血管病杂志, 2020, 48(4): 280-286.], articleTitle=超高危动脉粥样硬化性心血管疾病患者血脂管理中国专家共识, refAbstract=null)], funds=[Fund(id=1208144414308942585, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, awardId=2016YFC1300304, language=EN, fundingSource=National Key Research and Development Program of China(2016YFC1300304), fundOrder=null, country=null), Fund(id=1208144414401217280, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, awardId=2016YFC1300304, language=CN, fundingSource=国家重点研发计划(2016YFC1300304), fundOrder=null, country=null), Fund(id=1208144414527046408, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, awardId=Z181100006218055, language=EN, fundingSource=Beijing NOVA Program(Z181100006218055), fundOrder=null, country=null), Fund(id=1208144414648681233, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, awardId=Z181100006218055, language=CN, fundingSource=北京市科技新星计划(Z181100006218055), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1208144412329230993, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, xref=1, ext=[AuthorCompanyExt(id=1208144412333425298, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, companyId=1208144412329230993, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹Medical School of Chinese PLA, Beijing 100853, China), AuthorCompanyExt(id=1208144412341813907, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, companyId=1208144412329230993, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹解放军医学院，北京 100853)]), AuthorCompany(id=1208144412408922775, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, xref=2, ext=[AuthorCompanyExt(id=1208144412413117080, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, companyId=1208144412408922775, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=²Department of Cardiovascular Medicine, Chinese PLA General Hospital, Beijing 100048, China), AuthorCompanyExt(id=1208144412421505689, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1208144411159020139, companyId=1208144412408922775, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=²解放军总医院心血管病医学部，北京 100048)])], figs=null, attaches=null, journal=Journal(id=1146441329971666965, delFlag=0, nameCn=解放军医学杂志, nameEn=Medical Journal of Chinese People’s Liberation Army, nameHistory1=null, nameHistory2=null, issn=0577-7402, eissn=null, cn=11-1056/R, coden=null, periodic=0, language=CN, oaType=是, ccby=CC BY-NC-ND, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=6srot5PcoYX30Oa4xeTmeg==, journalPrice=null, startedYear=null, abbrevIsoEn=null, journalRemark=null, publicationField=null, createdTime=1751262512917, updatedTime=1761735725513, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=M, firstLetterEn=M, subjectCode=Life Sciences, subjectName=Life Sciences, subjectCodeEn=Life Sciences, subjectNameEn=null, picCn=6srot5PcoYX30Oa4xeTmeg==, picEn=ELwBh5xqrSTlIs7HmSNt2Q==, jcr=null, cjcr=null, exts=[JournalExt(id=1190369167564968109, language=CN, name=解放军医学杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1761735725537, updatedTime=1761735725537, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=#, submissionEditorUrl=#, submissionReviewUrl=#, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1190369167615299758, language=EN, name=Medical Journal of Chinese People’s Liberation Army, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1761735725549, updatedTime=1761735725549, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=#, submissionEditorUrl=#, submissionReviewUrl=#, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1189873630562394117, websiteList=[Website(id=1189873845923287108, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1189873630562394117, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/jfjyxzz/CN, language=CN, createTime=1761617631655, createBy=18614031015, updateTime=1761622010471, updateBy=18614031015, name=解放军医学杂志-中文, tplId=1146099689490845704, title=解放军医学杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1189924939378520839, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=articleTextType, value=kx, createTime=1761629813284, updateTime=1761629813284, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939353355012, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=banner, value=null, createTime=1761629813278, updateTime=1761629813278, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939399492362, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=grayFlag, value=0, createTime=1761629813289, updateTime=1761629813289, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939344966403, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=logo, value=https://castjournals.cast.org.cn/joweb/jfjyxzz/CN/file/pic?fileId=+zXjYVhun8ZOAA6+aKx2hw==, createTime=1761629813276, updateTime=1761629813276, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939412075276, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=minRunFlag, value=0, createTime=1761629813292, updateTime=1761629813292, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939374326534, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/jfjyxzz/CN/file/pic, createTime=1761629813283, updateTime=1761629813283, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939407880971, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=silenceFlag, value=0, createTime=1761629813291, updateTime=1761629813291, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939361743621, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1761629813280, updateTime=1761629813280, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939386909448, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=themeColor, value=null, createTime=1761629813286, updateTime=1761629813286, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939395298057, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=themeStyle, value=null, createTime=1761629813288, updateTime=1761629813288, creator=18614031015, updator=18614031015)]), Website(id=1189873846057504839, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1189873630562394117, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/jfjyxzz/EN, language=EN, createTime=1761617631687, createBy=18614031015, updateTime=1761622030030, updateBy=18614031015, name=解放军医学杂志-英文, tplId=1146101810881728533, title=Medical Journal of Chinese People’s Liberation Army, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1189924968168223505, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=articleTextType, value=kx, createTime=1761629820148, updateTime=1761629820148, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968147251982, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=banner, value=null, createTime=1761629820143, updateTime=1761629820143, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968185000724, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=grayFlag, value=0, createTime=1761629820152, updateTime=1761629820152, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968138863373, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=logo, value=https://castjournals.cast.org.cn/joweb/jfjyxzz/EN/file/pic?fileId=+zXjYVhun8ZOAA6+aKx2hw==, createTime=1761629820141, updateTime=1761629820141, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968197583638, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=minRunFlag, value=0, createTime=1761629820155, updateTime=1761629820155, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968159834896, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/jfjyxzz/EN/file/pic, createTime=1761629820146, updateTime=1761629820146, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968193389333, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=silenceFlag, value=0, createTime=1761629820154, updateTime=1761629820154, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968155640591, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1761629820145, updateTime=1761629820145, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968172417810, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=themeColor, value=null, createTime=1761629820149, updateTime=1761629820149, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968180806419, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=themeStyle, value=null, createTime=1761629820151, updateTime=1761629820151, creator=18614031015, updator=18614031015)])], journalTitle=解放军医学杂志, weixinUrl=null, journalUrl=http://zh.jfjyxzz.org.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Medical Journal of Chinese People’s Liberation Army, journalPhotoCn=6srot5PcoYX30Oa4xeTmeg==, journalPhotoEn=ELwBh5xqrSTlIs7HmSNt2Q==, journalFirstLetter=M, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false), detailUrlCn=https://castjournals.cast.org.cn/joweb/jfjyxzz/CN/10.11855/j.issn.0577-7402.2022.03.0292, detailUrlEn=https://castjournals.cast.org.cn/joweb/jfjyxzz/EN/10.11855/j.issn.0577-7402.2022.03.0292, pdfUrlCn=https://castjournals.cast.org.cn/joweb/jfjyxzz/CN/PDF/10.11855/j.issn.0577-7402.2022.03.0292, pdfUrlEn=https://castjournals.cast.org.cn/joweb/jfjyxzz/EN/PDF/10.11855/j.issn.0577-7402.2022.03.0292, aliStartDate=null, aliEndDate=null, collectionFlag=false, citedCount=null, citedUrl=null, reference=null)